mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021

• DOI: 10.1111/irv.12970
• Publication Date: 2022-02-18T09:39:54Z
• Authors: Huong Q. McLean; David L. McClure; Jennifer P. King; Jennifer K. Meece; David Pattinson; Gabriele Neumann; Yoshihiro Kawaoka; Melissa A. Rolfes; Edward A. Belongia
• Keywords: Rural Population; COVID-19 Vaccines; SARS-CoV-2; Short Communications; COVID-19; Vaccine Efficacy; 3. Good health; 03 medical and health sciences; Wisconsin; 0302 clinical medicine; Humans; Prospective Studies; RNA, Messenger

AbstractReduced COVID‐19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS‐CoV‐2 Delta (B.1.617.2) variant. Two‐dose VE against laboratory‐confirmed SARS‐CoV‐2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time‐varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID‐19 vaccines overall, 65% for Moderna, and 50% for Pfizer‐BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID‐19 vaccines overall, 59% for Moderna, and 52% for Pfizer‐BioNTech.